Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

E-GEOD-48403

ABSTRACT: Transcription profiling by high throughput sequencing of advanced prostate cancer treated with androgen-deprivation therapy

OTHER RELATED OMICS DATASETS IN: PRJNA209978

PROVIDER: E-GEOD-48403 | ExpressionAtlas | 2025-01-24

REPOSITORIES: ExpressionAtlas

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	E-GEOD-48403-analysis-methods.tsv	Tabular
	E-GEOD-48403-analytics.tsv	Tabular
	E-GEOD-48403-analytics.tsv.undecorated	Tabular
	E-GEOD-48403-analytics.tsv.undecorated.unrounded	Tabular
	E-GEOD-48403-analytics.tsv.unrounded	Tabular

Items per page:

1 - 5 of 33

Similar Datasets

E-GEOD-51005

Project description:Next generation sequencing of advanced non-castrate prostate cancer treated with docetaxel chemotherapy

2025-01-24 | E-GEOD-51005 | ExpressionAtlas

E-GEOD-58966

Project description:Transcription profiling by high throughput sequencing in castration resistant prostate cancer cell lines

2025-01-24 | E-GEOD-58966 | ExpressionAtlas

E-GEOD-53470

Project description:Transcription profiling by high throughput sequencing of c-JUN and JUND knockdown prostate cancer PC3 cell lines

2025-01-24 | E-GEOD-53470 | ExpressionAtlas

The effect of androgen deprivation on human prostate xenograft tumor LuCaP35

Project description:Androgen deprivation is a standard of care front-line therapy for human prostate cancer, however, majority of patients will eventally develop resistance to androgen deprivation. In this study, using a human prostate cancer xenograft model -LuCaP35, we examiend the gene expression changes after castration. We compare the gene expression of 5 LuCaP35 xenografts from non-treated mice (Control), and 5 androgen-deprived LuCaP35 xenografts from castrated mice (Castration).

2011-12-06 | E-GEOD-33316 | biostudies-arrayexpress

Next generation sequencing of advanced non-castrate prostate cancer treated with docetaxel chemotherapy

Project description:Early chemotherapy for advanced/metastatic non-castration resistant prostate cancer (PCa) may improve overall patient survival. We studied the safety, tolerability and early efficacy of up-front docetaxel chemotherapy and androgen deprivation therapy (ADT) versus ADT alone for patients with newly-diagnosed advanced/metastatic PCa. As proof of concept, we undertook in vivo gene expression profiling by next generation RNA sequencing (RNA-Seq). Tumour biposies from 6 patients were taken before and after treatment with combined ADT and docetaxcel for 6 weeks

2014-09-18 | E-GEOD-51005 | biostudies-arrayexpress

Next generation sequencing of advanced non-castrate prostate cancer treated with docetaxel chemotherapy

2014-09-18 | GSE51005 | GEO

Expression data from MCRedAL Prostate Tumors

Project description:Prostate tumor cells growth is interconected to androgen signaling. Indeed, the main line of treatment for advanced prostate cancer is focused on inhibiting androgen signaling by either surgical or pharmacological castration (or androgen-ablation, e.g. degarelix). We used microarrays to detail the global programme of gene expression following androgen-deprivation therapy (ADT) and identified distinct classes of up-regulated genes during this process that could contribute to the development of castration resistance.

2021-04-06 | GSE171491 | GEO

E-MTAB-2399

Project description:Transcription profiling by high throughput sequencing of human monocytes treated with lipopolysaccharide

2025-01-23 | E-MTAB-2399 | ExpressionAtlas

E-GEOD-51403

Project description:Transcription profiling by high throughput sequencing of MCF7 cell treated with E2

2025-01-24 | E-GEOD-51403 | ExpressionAtlas

E-GEOD-44379

Project description:Transcription profiling by high throughput sequencing of 293S cells treated with arsenite

2025-01-24 | E-GEOD-44379 | ExpressionAtlas